Skip to main content
MedPathMedPath Home
Clinical Trials/ISRCTN10756993
ISRCTN10756993
Active, not recruiting
未知

Preventing physical and psychological symptoms among cancer survivors through a mindfulness psychoeducation programme: a randomised controlled trial

ational University of Singapore0 sites210 target enrollmentApril 29, 2022
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsAlleviation of negative physical and psychological symptoms for cancer survivorsSigns and Symptoms

Overview

Phase
未知
Intervention
Not specified
Conditions
Alleviation of negative physical and psychological symptoms for cancer survivors
Sponsor
ational University of Singapore
Enrollment
210
Status
Active, not recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 29, 2022
End Date
August 31, 2026
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
ational University of Singapore

Eligibility Criteria

Inclusion Criteria

  • •Current inclusion criteria as of 29/08/2024:
  • •1\. Adults of any gender aged 21 to 75 years
  • •2\. Having a confirmed diagnosis of any type of cancer stage 0 to III by their attending physician
  • •3\. Have completed all cancer and related treatments (such as chemotherapy, surgery, and radiotherapy, as prescribed by their attending physician), with the exception of hormonal therapy between 2 weeks to 2 years (Lengacher et al., 2016\)
  • •Previous inclusion criteria:
  • •1\. Adults of any gender aged 21 to 65 years
  • •2\. Having a confirmed diagnosis of any type of cancer stage 0 to III by their attending physician
  • •3\. Have completed all cancer and related treatments (such as chemotherapy, surgery, and radiotherapy, as prescribed by their attending physician), with the exception of hormonal therapy between 2 weeks to 2 years (Lengacher et al., 2016\)

Exclusion Criteria

  • •1\. Having a diagnosis of severe mental disorders (e.g., schizophrenia, mood disorders, bipolar disorder, and substance\-related disorders)
  • •2\. Having a severe medical condition requiring hospitalisation
  • •3\. Is pregnant

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Prevention of depressive symptoms, anxiety, distress and irrational thoughts among victims of cyberbullying on the Vmbo through an online tailored advice.
NL-OMON39069Open Universiteit3,570
Completed
Phase 2
Prevention of the progression of very early symptoms into ankylosing spondylitisankylosing spondylitisspondyloarthritis10023213
NL-OMON36697Vrije Universiteit Medisch Centrum80
Completed
Not Applicable
Preventive Methods for Reduction of Pain associated with Propofol Injection: a randomised controlled trial of commonly used methodsPain Injection10001316
NL-OMON36046Catharina-ziekenhuis436
Active, not recruiting
Phase 1
Hydrocortisone as co-treatment to prevent neuropsychiatric adverse effects of dexamethasone.europsychiatric adverse effects which can be caused by dexamethasone. For example delirium, anxiety, depression, mania and psychosis. But also cognitive impairment and sleep disturbance.Therapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]
EUCTR2017-003705-17-NLMC180
Recruiting
Phase 4
Prevention of neuropsychiatric adverse effects caused by dexamethasone: insights from a placebo-controlled trial with hydrocortisone.
NL-OMON54782eids Universitair Medisch Centrum180